Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen-Cilag Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle-cell lymphoma (MCL), and is initiating ibrutinib therapy or has initiated ibrutinib therapy on or after 21 November 2014 (date of ibrutinib commercialization) for:
1. treatment of CLL/SLL in participants who have received at least 1 prior therapy; or
2. treatment in first line CLL/SLL participants in the presence of deletion (del) 17p or TP53 mutation in participants unsuitable for chemo-immunotherapy; or
3. treatment of participants with relapsed or refractory MCL
Not currently participating in another investigational study, clinical study, or any expanded access program at study entry
Has not participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program
Participant must sign a written informed consent form (ICF) allowing data collection and source data verification
You may not be if
Currently participating in another investigational study, clinical study, or any expanded access program at study entry
Participated in the ibrutinib Autorisation Temporaire d'Utilisation (ATU) program
Clareo Health | A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
